NCT06497439View on ClinicalTrials.gov

Efficacy and Safety of Silfamin for Common Cold

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 12, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Common ColdSore-throat
Interventions
DRUG

Silfamin

2 tablets of Silfamin 150 mg twice daily

DRUG

Placebo tablet of Silfamin

2 tablets of Silfamin Placebo twice daily

Trial Locations (2)

10430

IMERI Faculty of Medicine, University of Indonesia, Jakarta Pusat

16425

Makara UI Satellite Clinic, Depok

Sponsors

Lead Sponsor

Dexa Medica Group
All Listed Sponsors
collaborator

Fakultas Kedokteran Universitas Indonesia

OTHER

lead

Dexa Medica Group

INDUSTRY

NCT06497439 - Efficacy and Safety of Silfamin for Common Cold | Biotech Hunter | Biotech Hunter